In cross-sectional studies, elevated homocysteine levels are associated with higher blood pressure, but it remains unclear whether plasma homocysteine is a risk factor for hypertension. In a prospective nested case-control study, participants who developed hypertension (n ¼ 396) had significantly higher levels of baseline plasma homocysteine (12.6 lmol/l) than matched controls (11.8 lmol/l, P ¼ 0.03); compared to those in the lowest quintile, those in the highest quintile had a crude relative risk (RR) of 1.56 (95% confidence interval (CI), 0.98-2.48; P for trend ¼ 0.10) and a multivariable RR of 1.63 (95% CI, 0.97-2.74; P for trend ¼ 0.13). Higher plasma homocysteine levels at baseline were associated with an increased but non-significant risk of incident hypertension that was minimally affected by multivariable adjustment.
Hypertension is a common, chronic condition and most cases have an unclear etiology. 1 In crosssectional studies, higher plasma homocysteine levels are associated with higher levels of systolic blood pressure (SBP) and diastolic blood pressure (DBP), 2, 3 but it remains unclear as to whether this relationship extends to the development of hypertension. 4 ,5 Therefore, we used a prospective nested case-control study design to evaluate whether higher plasma homocysteine levels at baseline are associated with an increased risk of developing hypertension among men free of cardiovascular disease (CVD) at baseline and followed prospectively for 17.5 years.
Study subjects were participants in the Physicians' Health Study (PHS), a randomized trial of low-dose aspirin and b-carotene in the primary prevention of CVD and cancer. 6 Briefly, the PHS consisted of 22 071 apparently healthy male physicians without prior history of CVD, cancer (except non-melanoma skin cancer), current liver disease, kidney failure or insufficiency, or other major illnesses. The study was approved by the Institutional Review Board at the Brigham and Women's Hospital (Boston, MA, USA) and all study participants gave written informed consent.
Baseline information was self-reported by mailed questionnaire on demographic, medical history, and lifestyle characteristics. A total of 14 916 (68%) men also returned voluntary non-fasting blood samples that were immediately frozen and stored at À821C. Among the 9463 men initially free of hypertension who provided a blood sample, 4857 developed hypertension. We randomly selected 396 cases of incident hypertension (defined as SBPX140 mm Hg or DBPX90 mm Hg or new antihypertensive medication) for the analysis of plasma homocysteine levels. For each case, one control subject was selected among men who remained free of hypertension not only through the index date of the matched hypertension case but also through the remainder of follow-up. Controls were matched on age (71 year) and follow-up time (73 months). The paired, blinded plasma samples were shipped on dry ice to the Core Laboratory of the Children's Hospital (Boston, MA, USA) where plasma samples remained frozen until selected and analysed for this study. 7 Plasma homocysteine levels for cases and controls were assayed using the IMx homocysteine assay (Abbott labs, Abbott Park, IL, USA). Case-control pairs were blinded throughout handling, shipping, and assaying of blood samples.
Means or proportions for baseline characteristics were compared for cases and controls using Student's t-test or w 2 -test. We created quintiles based upon the distribution of plasma homocysteine found in 396 controls and risk factors were compared using w 2 -tests for categorical variables, and analysis of variance for continuous variables. We calculated relative risks (RRs) and 95% confidence intervals (CIs) using conditional logistic regression in Model no. 1 that accounted for the matching variables (age and follow-up time). Model no. 2 adjusted for parental history of myocardial infarction before age 60 years, alcohol use (rarely/never, o1 per day or X1 per day), cigarette smoking (never, past, o15 cigarettes per day, X15 cigarettes per day) and vigorous exercise (rarely/never, o2 times per week or X2 times per week). Model no. 3 also adjusted for body mass index (kg/m 2 ), history of diabetes and history of hyperlipidemia (either selfreported total cholesterol X240 mg/dl or treatment). Model no. 4 further adjusted for multivitamin use (past/never or current), whereas Model no. 5 also included baseline SBP and DBP. All statistical analyses were performed in SAS version 9.1 (Cary, NC, USA).
Participants who developed hypertension had a higher body mass index (Po0.01) and higher baseline SBP and DBP compared to controls. The mean homocysteine level was 12.675.0 mmol/l in cases and 11.874.0 mmol/l in controls (P ¼ 0.03) ( Table 1) . When controls were divided into quintiles based on homocysteine level, those who took multivitamin supplements (which likely included folate, vitamin B12 and vitamin B6) had lower levels of plasma homocysteine (Po0.01) ( Table 2 ). RRs and 95% CIs for hypertension according to increasing quintiles of homocysteine are shown in Table 3 . Compared to those in the lowest quintile of plasma homocysteine, increasing quintiles of plasma homocysteine had crude RRs of 1.27, 1.45, 1.28 and 1.56 (P, trend ¼ 0.10) that were not notably attenuated after step-wise adjustment for lifestyle and clinical factors.
Our results are consistent with a prospective relationship between baseline plasma homocysteine level and subsequent risk of developing hypertension, a common diagnosis in the United States with unclear risk factors.
1 Although higher plasma homocysteine levels have been associated with elevated blood pressure in cross-sectional studies, 2,3 the Framingham Heart Study is the only prospective study to evaluate a causal relationship. 8 In the Framingham cohort, homocysteine was associated with an increased risk of hypertension in the unadjusted model, but multivariable adjustment reduced any risk relationship to the null. In our cohort of healthier and younger men with higher levels of plasma homocysteine and longer followup, the crude risk estimates were not materially affected by multivariable adjustment. Clinical trials are currently underway that will assess how folicacid-based interventions may reduce the risk of cardiovascular disease, 9 and it will be informative to understand any blood pressure effects that may be attributable to folic acid.
Our prospective study has several strengths and potential limitations. Because the relationship between plasma homocysteine and hypertension may be subject to confounding, 10 we considered many clinical and lifestyle variables such as alcohol intake and multivitamin use; however, as in any observational study, it is possible that residual confounding may have affected our results. Undetected chronic renal disease may also affect plasma homocysteine levels, although all participants indicated that they were free of known renal disease at baseline. To further investigate whether our study cohort was free of chronic renal disease, we analysed available baseline plasma creatinine levels in a subset of 424 (54%) participants. The mean baseline plasma creatinine levels in 222 hypertension cases and 
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202 normotensive controls were 1.0170.14 and 1.0170.14 mg/dl (P ¼ 0.82), indicating that substantial confounding by impaired renal function would be unlikely in this population of initially healthy, normotensive male physicians. The generalizability of our results may be limited as our study population consisted of male physicians, but this may also reduce potential confounding by reducing 11 however, our data may have been subject to modest random misclassification bias that would have biased our results to the null. Finally, our prospective study occurred before wide-spread folic acid fortification of enriched grain products, a 1998 US public health intervention that led to an improvement in folate status and a decrease in plasma homocysteine levels. 12 In summary, higher baseline plasma homocysteine levels were positively but non-significantly associated with an elevated risk of developing hypertension. Our prospective results add to a limited literature and underscore the importance of clarifying potential mechanisms by which plasma homocysteine levels may identify those at risk for developing hypertension. More prospective studies and clinical trials focused on plasma homocysteine and blood pressure will improve our understanding of these associations with the goal of reducing the public health burden of hypertension.
